Enoxolone for depression, using body signals to track response
Part of Mental health clinical trials.
This study tests enoxolone, a medication related to licorice, in people with unipolar (non-bipolar) major depression. It also looks at your body “signals” (biomarkers) to see which ones match with whether treatment helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have unipolar major depression (not bipolar disorder).
- If you are a woman, you must use reliable birth control during the study.
- You should not be pregnant or trying to become pregnant during the study.
- You cannot have certain mental health conditions like schizophrenia or delusional disorders.
- You should not have certain nervous system diseases (like epilepsy) or serious intellectual disability.
- Your heart, blood pressure, and electrolytes must be safe (no very high blood pressure, low potassium, or concerning ECG results).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests OSU6162 added to an SSRI or SNRI in people whose major depression did not improve enough after trying specific antidepressants for at least 6 weeks. It may help reduce depression symptoms when standard treatments haven’t worked well.
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
This study measures changes in your blood and/or body chemistry while you receive electroconvulsive therapy (ECT) for a severe mood episode. The goal is to understand biological signals related to ECT and treatment-resistant depression, which may help improve future care.
This trial tests a new medicine called LV232 for people with moderate to severe depression. Researchers want to find the best dose and check if it works safely.
This study tests whether a new medication called TNX-102 SL can reduce depression symptoms better than a placebo (inactive pill). You'll take the medication daily and have regular check-ins to see how you're doing.
This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.
Hear when a new Unipolar Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.